SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalGMED - GenoMed Inc.


Previous 10 Next 10 
From: jmhollen4/12/2006 1:02:22 PM
   of 347
 
GenoMed Agrees to Distribute Healthcare to India for Under $150 Per Patient Per Year

FOR IMMEDIATE RELEASE

Contact:

David Moskowitz MD
CEO, GenoMed, Inc.
St. Louis, Missouri
www.genomed.com
Tel. 314-983-9933
Email: dwmoskowitz@genomed.com

Ms. Sujata Mital
Director, SUMIT Exports & Trades pvt. Ltd.
Mumbai, India
www.sumitbiomedical.com
Email: sumit_exports@yahoo.com

ST. LOUIS, April 12, 2006 -- GenoMed, Inc. (Pink Sheets GMED) a Next Generation Disease Management company whose business is public health™, announced today that it has entered into an exclusive agreement with SUMIT Exports & Trades to market its services to India for under US $150 per patient per year. Since the per capita income in India is around $600 a year, GenoMed has priced its Next Generation DM™ service within reach of the average Indian citizen.

Dr. David Moskowitz, GenoMed's CEO and Chief Medical Officer, said, "In 2002, we published that we can reverse chronic kidney failure from diabetes and high blood pressure, as well as significantly delay the progression of emphysema. Third World countries like India want to enjoy better health, but can't afford to spend $2 trillion a year on healthcare as the U.S. currently does. Thanks to medical genomics, GenoMed can already deliver better outcomes for cardiovascular disease, which two-thirds of people in First World countries like the U.S. die of. And we have a good jump on cancer, which a third of Americans die of."

Continued Dr. Moskowitz, "Yesterday, at the BIO 2006 convention in Chicago, former President Clinton called biotechnology the answer to international healthcare. Today, we're delighted to prove him right. We look forward to the expansion of President Bush's Health Savings Accounts (HSA's) to make preventive molecular medicine and lower health care costs a reality in the United States one day, too."

About GenoMed™

GenoMed is the only biotechnology company serious about both lowering healthcare costs and improving patient outcomes. It is leading the clinical revolution made possible by knowing which genes cause which diseases. GenoMed is currently marketing its protocols to prevent kidney failure due to high blood pressure and diabetes, and to delay the progression of emphysema. The company is offering its Healthchip®, on a research basis only, to predict breast, colon, lung, ovarian, pancreatic, and prostate cancer in Caucasians. And GenoMed is in the process of creating a virtual pharmaceutical company to develop new drugs for the hundreds of cancer chemotherapy targets it has discovered, in situations where no drug yet exists.


Share RecommendKeepReplyMark as Last Read


From: jmhollen4/19/2006 9:52:11 AM
   of 347
 
GenoMed to Offer Free Mumps Trial

Contact: David Moskowitz MD
CEO, GenoMed, Inc.
Tel. 314-983-9938
Email: dwmoskowitz@genomed.com

ST. LOUIS—April 19, 2006--GenoMed Inc.-- ("the Company" or "GenoMed") (National Quotation Bureau's Pink Sheets Symbol: GMED.PK) a St. Louis, Missouri-based Next Generation Disease Management company whose business is public health™, announced today that it is offering a free clinical trial for mumps, using already existing medications. (The cost of the drugs, about $1 a day, is extra).

GenoMed believes a class of safe, already existing blood pressure pills may be a near-universal viral antidote, making vaccines and antiviral drugs unnecessary for most viruses except for the tiny fraction of the population which is immunosuppressed. GenoMed's approach has been successful for treating West Nile virus encephalitis in humans for the past 3 summers, and in birds for the past 2 summers. The first 8 patients were published in a peer-reviewed medical journal in 2004.

Said David Moskowitz, MD, GenoMed's CEO and Chief Medical Officer, "Unlike West Nile virus, the mumps virus is no more lethal than the common cold, but it causes a lot of discomfort. As with most viruses, disease in humans is caused by a 'cytokine storm,' not by the virus itself. Our approach is to calm the 'cytokine storm' in the host and ignore the virus. Our goal is to turn the patient into an asymptomatic shedder, which is what happens normally."

Added Dr. Moskowitz, "Our approach should work for most viruses in most people and animals. The more experience we get with different viruses, the more credible this approach becomes, and the readier we'll be for something really big, like avian flu or a viral bioterrorist attack."

GenoMed holds a pending patent for its approach in the U.S. but not the rest of the world. It was included in the Project BioShield Act of 2005 co-sponsored by Senators Lieberman, Hatch, and Brownback (see Section 2151 of Senate bill S.975, available at: govtrack.us. Introduced a year ago, this bill has not yet been discussed. The White House requested a briefing about GenoMed's possible viral antidote in the summer of 2004, and the Department of Homeland Security and the National Institutes of Health agreed to a briefing in the fall of that year. For the past three years, the World Health Organization has not returned any phone calls or emails on this subject. The Centers for Disease Control complained to the FDA about GenoMed's West Nile virus trial in June, 2004, but the FDA dropped the case as soon as it began investigating it in August, 2005.

To enroll in GenoMed's free clinical trial for mumps, simply contact Dr. Moskowitz.

About GenoMed

GenoMed is a Next Generation DM(tm) company that has found what it believes to be the "master" disease gene. It has already been able to prevent kidney failure due to diabetes and hypertension in whites, blacks and Hispanics; dramatically delay the progression of end-stage emphysema; and begin to see success in treating cancer and autoimmune diseases. GenoMed's near-universal viral antidote is simply another consequence of the "master" disease gene, which alone promises to revolutionize healthcare globally. Despite the usual obstacles facing any biotech start-up company, GenoMed perseveres in its mission to improve public health through genomics, promising a significant return to both patients and shareholders.

.

Share RecommendKeepReplyMark as Last Read


From: Tadsamillionaire5/12/2006 9:05:12 PM
   of 347
 
MO Rep. Mott Oxford Congratulates GenoMed on Reversing Kidney Failure
ST. LOUIS, May 2 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is public health(TM), announced today that Missouri State Representative Jeanette Mott Oxford has offered her congratulations to GenoMed on its novel treatment for chronic kidney failure.

GenoMed was the first to prove that chronic kidney failure may not be so chronic after all, at least early in its course. GenoMed's CEO, David Moskowitz MD, showed that chronic kidney failure due to diabetes or high blood pressure can actually be reversed early in the course of the disease.

Said the Honorable Ms. Mott Oxford, Representative for Missouri's 59th House District, 'Prevention of dialysis will save federal dollars and allow a much better quality of life for Missourians. The State of Missouri will benefit from healthier, more productive people who can continue to help others, rather than be a burden themselves.'

Rep. Mott Oxford continued, 'I am particularly excited by the implication this has for our state Medicaid budget. If kidney disease from diabetes and high blood pressure can be controlled, then maybe heart disease and other complications can be, too. If so, the cost of cardiovascular disease could finally be reduced in Missouri.'

Rep. Mott Oxford added, 'Dr. Moskowitz came to my attention a few years ago when he fought for a friend of mine with emphysema to receive proper treatment in a system that wanted to deny him needed medicines. As time has passed, my admiration has only grown.'

Dr. Moskowitz was recently presented with the 2006 Defender of Patient Safety Award (physician category) by Missouri Watch ( missouriwatch.net ). His results were published in Diabetes Technology and Therapeutics, a peer-reviewed medical journal, in September, 2002. If applied nationally, Dr. Moskowitz's method could prevent up to 90% of dialysis, and save Medicare over $22 billion a year. GenoMed owns the patents pending for this novel treatment approach

Share RecommendKeepReplyMark as Last Read


From: donpat6/22/2006 8:52:16 AM
   of 347
 
Hi - Tad, JM - is this GMED any good? Worth following? EM

Share RecommendKeepReplyMark as Last ReadRead Replies (2)


To: donpat who wrote (298)6/22/2006 9:55:53 AM
From: jmhollen
   of 347
 
They seem to have the goods, but they're bucking the snooty AMA establishment.

If they had/received the funding to do proper marketing and break out, it could be a good one.

John :-)

.

Share RecommendKeepReplyMark as Last Read


To: donpat who wrote (298)6/28/2006 7:45:37 PM
From: Tadsamillionaire
   of 347
 
GenoMed CEO Invited to Lecture at University of Chicago About Bird Flu
ST. LOUIS, June 21 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is global public health(TM), today announced that its CEO was invited to speak at the Department of Medicine of the University of Chicago about diseases associated with the angiotensin I-converting enzyme (ACE), including avian influenza ('bird flu').

Dr. Skip Garcia, Chairman of the Medicine Department, invited GenoMed's CEO, David Moskowitz, MD, for a two day Visiting Lectureship that ended yesterday. Dr. Garcia is a world-famous lung specialist whose research group is looking for drugs to decrease the 'cytokine storm' created by the avian influenza virus.

GenoMed has filed patent applications claiming that ACE inhibitors and angiotensin II blockers can do exactly that. Furthermore, these drugs may be a near-universal viral antidote, because people who get sick from all viral diseases suffer from a 'cytokine storm.' GenoMed's viral antidote was included in the Project BioShield II Act of 2005, since it would be an ideal response to viral bioterrorism.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, 'GenoMed goes from the molecular mechanism of disease directly to practical treatments that are safe and useful at the population level. We're extremely gratified that a world-class research institution like the University of Chicago is thinking along exactly the same lines.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: Tadsamillionaire who wrote (300)6/28/2006 7:46:26 PM
From: Tadsamillionaire
   of 347
 
GenoMed Can Explain Link Between West Nile, Diabetes/Hypertension
ST. LOUIS, June 26 /PRNewswire-FirstCall/ -- GenoMed (Pink Sheets: GMED), a Next Generation Disease Management company whose business is global public health(TM), today announced that it has already published why patients with diabetes and high blood pressure should be at increased risk of getting West Nile virus encephalitis.

This observation has now been made in California, New York and Texas.

The link appears to be over-activity of the angiotensin I-converting enzyme, abbreviated 'ACE.'

In 2002, GenoMed published a series of four papers showing that over- activity of ACE led to diabetes and hypertension, as well as to complications like heart and kidney disease. Using the right dose of the right ACE inhibitor, it was possible to reverse diabetic or hypertensive kidney disease for the first time.

In 2004, GenoMed published that a similar approach was successful in treating over 80% of patients with West Nile virus encephalitis. GenoMed's treatment success rate for WNV encephalitis is currently 86% (19 of 22 patients improved rapidly).

In 2003, GenoMed filed patent applications claiming that ACE inhibitors and angiotensin II blockers may be a near-universal viral antidote, because previously healthy people who get sick from nearly all viral diseases suffer from a 'cytokine storm' initiated by too much angiotensin II. Angiotensin II is made by ACE. GenoMed's viral antidote was included in the Project BioShield II Act of 2005, since it would be an ideal public health response to viral bioterrorism.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, 'GenoMed goes from the molecular mechanism of disease directly to practical treatments that are safe and useful at the population level. It's very gratifying to get separate epidemiologic confirmation that we've discovered something huge.'

Share RecommendKeepReplyMark as Last Read


From: jmhollen6/29/2006 4:18:21 PM
   of 347
 
(eMail): MN1.com Press Conference for GenoMed

ST. LOUIS, MO, Jun 29, 2006 – GenoMed, Inc. (PINKSHEETS: GMED) will conduct a live press conference on www.MN1.com at 9:30am Central Time Friday, June 30th, 2006. Interested parties may go to www.MN1.com and download the free player enabling them to listen in for management's review of operations and discussion of future prospects. This live broadcast is available to anyone at any computer connected to the Internet. This should prove to be an eye-opening and enriching experience for all of those associated with GenoMed (PINKSHEETS: GMED).

About MN1.com

MN1.com is the only online destination that brings real microcap news to investors and features live interaction with companies from the Bulletin Board, Pink Sheets, and Amex. Featuring Live Press Conferences, All-Day Live Trading Commentary, Analyst Profiles, Interactive Forums, News Items, and "The MicroBlog," MN1.com gives microcap investors the information source necessary to trade in the markets. MN1.com boasts being the largest true news company reporting on microcap traded stocks.

About GenoMed

GenoMed (PINKSHEETS: GMED) is a St. Louis-based Next Generation Disease Management company that uses genomics to improve patient outcomes. Besides kidney disease, GenoMed has novel approaches to many additional diseases, including a general viral antidote. Anyone can download GenoMed's protocol for avian influenza or West Nile virus from GenoMed's website, www.genomed.com, at any time of day or night.

CONTACT: David Moskowitz MD
GenoMed, Inc.
www.genomed.com
Tel. 314-983-9938
SOURCE: GenoMed

.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)


To: jmhollen who wrote (302)8/4/2006 10:26:58 PM
From: Tadsamillionaire
   of 347
 
GenoMed's First Horse Recovers Quickly from Presumed West Nile Virus Encephalitis
ST. LOUIS, July 31 /PRNewswire-FirstCall/ -- GenoMed (OTC: GMED), a Next Generation Disease Management company that uses genomics to solve diseases in as many species as possible, today announced that the first horse in its expanded trial for West Nile virus encephalitis recovered completely within 24 hours after starting GenoMed's treatment.

Four days ago, a horse owner in Idaho contacted GenoMed to say that her horse had begun moving much more slowly, and that the veterinarian was treating it for West Nile virus encephalitis. Only two days before, another of her horses had to be put down for presumed West Nile virus encephalitis because it could no longer lift its head and eat.

Within 24 hours of starting GenoMed's treatment, the horse was 'quick on its feet' and appeared fully recovered. The horse's prompt recovery from West Nile virus encephalitis was like that GenoMed has observed since 2003 in people, and since 2004 in birds.

GenoMed's protocol uses a class of already existing blood pressure pills to block the brain inflammation caused by West Nile virus. This disease mechanism appears to be shared by all vertebrates infected with most viruses, leading GenoMed to believe it may have found a safe, general viral antidote. For this reason, GenoMed's approach was included in the language of the Project BioShield II Act of 2005, introduced by Senators Lieberman, Hatch, and Brownback. This bill has not yet been debated in the US Senate.

GenoMed's treatment success rate for WNV encephalitis in people is currently 86% (19 of 22 patients improved rapidly). A small case series involving the company's first 8 patients was published in a peer-reviewed medical journal in 2004.

Said Dr. Moskowitz, GenoMed's CEO and Chief Medical Officer, 'We're delighted that our anti-viral approach appears to work in yet another species. The veterinary community already treats West Nile virus encephalitis as an excessive inflammation of the brain, and is embracing our approach far more readily than the public health community. As a result, I'm afraid that we may save more horses than people this year.'

Share RecommendKeepReplyMark as Last Read


From: jmhollen8/8/2006 11:19:30 AM
   of 347
 
GenoMed's West Nile Virus Trial Endorsed by Emergency Medicine Authority

Neal Handly, MD
tel. 610.563.0664
nh28@drexel.edu

David W. Moskowitz MD
CEO, GenoMed
tel. 314.983.9933
dwmoskowitz@genomed.com

ST. LOUIS—August 8, 2006--GenoMed (OTC Pink Sheets GMED), a Next Generation Disease Management company whose business is public health™, today announced the endorsement of its trial for West Nile virus encephalitis by an authority in Emergency Medicine, Dr. Neal Handly.


Dr. Handly is Associate Director of Research for the Department of Emergency Medicine at Drexel University College of Medicine and a Fellow of the American Academy of Emergency Medicine. Dr. Handly chairs the Academy's Subcommittee on Information Technology.

Dr. Handly said, "GenoMed's protocol is extremely exciting, since we're in the grip of another West Nile epidemic this summer without any known treatment. The Emergency Room is where these cases are seen first. It makes sense to have the ER be a partner in a clinical trial."

Dr. Handly continued, "Dr. Moskowitz uses safe medicines already familiar to every ER physician. What makes his approach appealing is the possibility that it may work for many viruses, including avian influenza and bioterrorist viral attacks. These last two scenarios are of special concern to the Emergency Medicine community."

About Dr. Handly

Dr. Neal Handly is an Assistant Professor in the Department of Emergency Medicine at Drexel University College of Medicine in Philadelphia, PA. He was consulted to create a state-of-the-art ER this summer in Beirut, Lebanon but has been prevented from doing so by the current hostilities.

About GenoMed

Since 2003, GenoMed has been using safe, FDA-approved, prescription-only blood pressure pills to treat West Nile virus encephalitis. So far, GenoMed has had an 86% treatment success rate (19 of 22 patients). This summer the Company extended its trial successfully to include horses. Anyone can download the WNV trial protocol from GenoMed's website, www.genomed.com, by clicking on the "West Nile trial" link. An email address is required for clinical follow-up.

.

Share RecommendKeepReplyMark as Last Read
Previous 10 Next 10